Basal Cell Carcinoma Chemoprevention Trial
NCT05212246
This study is recruiting at 6 US sites in 6 states, according to its ClinicalTrials.gov record last updated .
Summary
This is an intent-to-treat, parallel design, multicenter randomized trial and the primary intervention is a double-blind comparison of imiquimod (IMQ) vs. placebo cream for preventing basal cell carcinoma (BCC) of the skin on the face at one year and over 3 years after therapy. Participants will apply the IMQ or placebo cream to the face daily at bedtime for 12 weeks. This study will recruit 1630 Veterans at high risk of BCC from 17 VA medical centers.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Basal Cell Carcinoma
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 3
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- VA Office of Research and Development
- Last updated on ClinicalTrials.gov
- October 19, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- VA San Diego Healthcare System, San Diego, CA · San Diego, CA
Florida · 1
- Bay Pines VA Healthcare System, Pay Pines, FL · Bay Pines, FL
Minnesota · 1
- Minneapolis VA Health Care System, Minneapolis, MN · Minneapolis, MN
North Carolina · 1
- Durham VA Medical Center, Durham, NC · Durham, NC
Utah · 1
- VA Salt Lake City Health Care System, Salt Lake City, UT · Salt Lake City, UT
Wisconsin · 1
- Clement J. Zablocki VA Medical Center, Milwaukee, WI · Milwaukee, WI
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.